AKTS · Aktis Oncology, Inc.
$24.00
-1.02 (-4.08%)
At close · Aug 20
Market Cap
$1.33B
Shares
55.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.00
Open$24.75
Day$23.44–24.75
Available close range$15.19–32.23
Avg vol 30d292K
Short int3.5M · 6.2% float · 12.8d
Short vol42%
DataJan 2026–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Jan 9, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−4%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
52%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+19%
trailing
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+64% holders QoQ · +52 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Falling
6.24% of float · ▼ -7.2% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Squeeze score
62
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−4%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+64% holders QoQ · +52 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Falling
6.24% of float · ▼ -7.2% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Price context
position in its available closing range
Range low $15
Now $24 · 52%
Range high $32
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTS
this stock
Aktis Oncology, Inc.
|
$1.33B | — | — | — | 6.2% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTS | +0.9% | 0.0% | +19.2% | +8.7% | — |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.8% | -3.4% | +8.1% | +6.7% | — |
Key facts
CIK
2035832
CUSIP
01021M104
13F (30d)
105 filings
105 filers
Visit website
Investor relations